Cubist Pharmaceuticals, Inc. is a biopharmaceutical company focused on the research, development, and commercialization of pharmaceutical products that address unmet medical needs in the acute care environment. In the U.S., Cubist markets CUBICIN® (daptomycin for injection), the first antibiotic in a class of anti-infectives called lipopeptides.   Cubist also has an agreement with Optimer Pharmaceuticals, Inc. to co-promote Optimer's drug, DIFICID™ (fidaxomicin), in the U.S. as a treatment of Clostridium difficile-associated diarrhea (CDAD).  The Cubist clinical product pipeline currently consists of a Phase 3 program focused on the development of a novel cephalosporin to address certain serious infections caused by multi-drug resistant (MDR) Gram-negative organisms and a Phase 2 program for the treatment of CDAD. Cubist also is working on several pre-clinical programs being developed to address areas of significant medical needs. These include therapies to treat various serious bacterial infections and agents to treat acute pain.

Headquartered in Lexington, Massachusetts, Cubist employs more than 600 people — approximately 380 in Massachusetts. The company's total net revenues increased 13% to $636.4 million in 2010 from $562.1 million in 2009.  At Cubist, we believe our core strength is the broad range of individuals who make up our team. The variety of innovative ideas, knowledge, experiences, and cultures our employees bring to their work give us our greatest competitive advantage. Cubist. Cubist Jobs.Cubist Biotech Jobs.Cubist Diversity Jobs.Diversity Jobs.Pharma Jobs.Pharmaceutical Jobs.PharmaDiversity.PharmaDiversity Job Board. P

Career Opportunities

View Cubist Job Opportunities click here